Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry.

Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry.

Vitamin K antagonists (VKAs) need to be individually dosed. International guidelines recommend a target range of international normalised ratio (INR) of 2.0-3.0 for stroke prevention in atrial fibrillation (AF). We analysed the time in this therapeutic range (TTR) of VKA-treated patients with newly...

Full description

Bibliographic Details
Main Authors: Sylvia Haas, Hugo Ten Cate, Gabriele Accetta, Pantep Angchaisuksiri, Jean-Pierre Bassand, A John Camm, Ramon Corbalan, Harald Darius, David A Fitzmaurice, Samuel Z Goldhaber, Shinya Goto, Barry Jacobson, Gloria Kayani, Lorenzo G Mantovani, Frank Misselwitz, Karen Pieper, Sebastian M Schellong, Janina Stepinska, Alexander G G Turpie, Martin van Eickels, Ajay K Kakkar, GARFIELD-AF Investigators
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5085020?pdf=render

Internet

http://europepmc.org/articles/PMC5085020?pdf=render

Similar Items